Navigation Links
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Date:2/14/2008

o improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by applicable regulatory authorities, or if approved, will prove competitive in the market; and whether the necessary financing to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors, such as whether execution of the strategic plan for 2008 will result in maximizing the value of the company's lead compounds, whether the company will identify and enter into a strategic alliance with regard to any of the company's programs, and whether the company's reduction in headcount will have a significant impact on overall expenses of the company. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics annual report on Form 10-K for the year ended Dec. 31, 2006, as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Company Contact: Media Contact:

Ev Graham David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x118 212-845-4271

egraham@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact: Investor Contact:

Rhonda Chiger John Baldissera

Rx Communications
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
5. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
8. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
9. ImaRx Therapeutics Transitions Business Strategy
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
(Date:9/18/2014)... , Sept. 18, 2014   MacPractice,s MacPractice ... Edition Complete EHR certification, which designates that the software ... Stage 1 and Stage 2 Meaningful Use measures required ... Reinvestment Act (ARRA).  MacPractice MD MU version 5.0 was ... , an Office of the National Coordinator-Authorized Certification Body ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... 2011 Heska Corporation (NASDAQ: ... veterinary diagnostic and other specialty veterinary products , today ... best practices research, tools and metrics for patent analysis ... Heska,s Science Strength in the top 50 of the ...
... released by SCM: (Photo:   http://photos.prnewswire.com/prnh/20111006/LA81891 ) ... of closing statements, lead trial attorney for the plaintiffs in ... asked jurors to bring a verdict of $10 million in ... for James Arnold and to consider whether the Arnolds should ...
Cached Medicine Technology:The Patent Board, IP Tracking and Analysis Firm, Ranks Heska's Science Strength in Biotechnology Industry Top 50 2Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold 2
(Date:9/19/2014)... 2014 United Benefit Advisors (UBA), ... its annual Fall Meeting & Expo at the ... Illinois. With a fantastic attendance of more ... new CEO, Les McPhearson, led these thought leaders ... what is required of successful advisor firms looking ...
(Date:9/19/2014)... September 19, 2014 Script Relief, ... on all commonly prescribed high blood pressure medications. ... drug coupons and has saved its users over ... of making prescription medications more accessible and affordable, ... blood pressure medications. , High blood pressure, also ...
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Fiber Transport Services, adding Point of Presence (PoP) at ... PoP at Cermak, IFN enables interconnect opportunities for Carriers, ... fiber transport service to US and Global Carriers. ... Sales and Marketing August Zehner, establishing a PoP at ...
(Date:9/19/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Potassium Chloride . , The FDA announced on ... lot of Potassium Chloride Injection 10mEq per 100mL due to ... intravenously, is used to treat potassium deficiency. , The ... on the shipping cartons in a single lot where, for ...
(Date:9/19/2014)... A McLean County woman filed ... following a failed hip replacement using a DePuy XL ... Inc. and Johnson & Johnson over allegations that they ... nationally known personal injury law firm, represents defective hip ... involving defective hips. , According to the lawsuit, Owens ...
Breaking Medicine News(10 mins):Health News:United Benefit Advisors New CEO Presides Over Fall Meeting & Expo 2Health News:United Benefit Advisors New CEO Presides Over Fall Meeting & Expo 3Health News:HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications 2Health News:HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications 3Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2
... ... Fresh, Nutritious, and Creative , ... Santa Cruz, CA (Vocus) June 18, 2010 -- School’s about to start and so ... J? Switch it up with kids’ bento boxes , from Laptop Lunches. ...
... ... people of all faiths in Dallas, TX, on June 27th and 28th, 2010. Spiritual ... her love and compassion in person. , ... Dallas, TX (PRWEB) June 18, 2010 -- The ‘Hugging Saint’ Amma ( http://www.amma.org ...
... ... their new 360 Degree Guarantee and provide consumers with coverage that extends past the original ... by a standard warranty. , ... (PRWEB) June 18, 2010 -- Treadmill Doctor has announced the introduction of their ...
... ... barometer for hiring this fall, we are about to see a significant pickup in recruiting from ... (PRWEB) June 18, 2010 -- ... leading indicator for future hiring activity. “It only makes sense, says RD Whitney, CEO of Onrec ...
... ... industry lived up to its tagline - “Connecting you to good health” when it successfully ... , ... Makewell Meditour Ltd., a pioneer in India’s medical tourism industry lived up to ...
... trial of a new model for testing Alzheimer,s treatments has ... exacerbate the disease if treatment is interrupted. Scientists at ... & Co. Inc studied the effects of a class of ... these drugs might cause a build-up of proteins linked to ...
Cached Medicine News:Health News:Kids' Lunchboxes Go Bento for Easy Back to School Lunch Making, Thanks to Laptop Lunches 2Health News:The ‘Hugging Saint' Amma Visits Dallas June 27-28, 2010, Offering Spiritual Upliftment to People of All Faiths 2Health News:Treadmill Doctor 360 Degree Guarantee Extended Service Plans 2Health News:Onrec Predicts Significant Recruiting Activity this Fall 2Health News:Onrec Predicts Significant Recruiting Activity this Fall 3Health News:Onrec Predicts Significant Recruiting Activity this Fall 4Health News:Makewell Meditour Helps Nigerian Family Find a Facility to Perform Rare Separation Surgery for Conjoined Twins 2Health News:Makewell Meditour Helps Nigerian Family Find a Facility to Perform Rare Separation Surgery for Conjoined Twins 3Health News:New model suggests feared side effect of Alzheimer's drugs is unlikely 2
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
... Triad Plus Sterile ... Swabsticks are primarily used ... prior to administering injections. ... to meet AAMI/ANSI/ISO 11137 ...
Medicine Products: